May 21st 2025
Accropeutics reveals promising Phase 2 trial results for AC-201, a selective TYK2/JAK1 inhibitor, showing significant efficacy in treating plaque psoriasis.
May 19th 2025
Albert Chiou, MD, MBA, discusses early clinical data on soquelitinib for atopic dermatitis, highlighting its targeted ITK inhibition, dose-dependent efficacy, favorable safety profile, and more.
May 15th 2025
Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.
May 9th 2025
The promising safety and efficacy results were presented at the Society for Investigative Dermatology 2025 Annual Meeting.
May 8th 2025
Selective ITK inhibition with oral soquelitinib led to early and durable clinical responses, cytokine reduction, and increased T regulatory cells.
FDA Approves First Gene Therapy for RDEB
The FDA approved pz-cel, a groundbreaking gene therapy for recessive dystrophic epidermolysis bullosa, transforming treatment options for patients.
FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria
Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.
Hope on the Horizon: Expert Insights into Dupilumab for CSU
Having multiple therapeutic options would allow clinicians to tailor treatment and offer hope to patients who don't respond initially.
Exploring Off-Label Uses of Topical JAK Inhibitors
While approved for vitiligo and atopic dermatitis, ruxolitinib cream may help treat other inflammatory skin diseases.
Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates
Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025.
Quoin Files US Patent Applications for Rare Disease Treatments
The novel treatments will be for patients with orphan conditions like Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and palmoplantar keratoderma.
Potential Treatments for TSW Identified in NIH Study
A pilot study revealed that mitochondrial complex I-blocking drugs, like metformin and berberine, improved TSW symptoms in most participants.
L'Oréal Issues Voluntary Recall of Benzoyl Peroxide Products Over Benzene Concerns
The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.
Medicus Reports Promising Interim Results for Non-Invasive BCC Treatment
Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.
Almirall Showcases Therapeutic Innovations at AAD 2025
The company showcased advancements in tirbanibulin and its early-stage antibody LAD191.
New Study Explores Benzoyl Peroxide-Related Adverse Events and Potential Neoplasm Signals
Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.
Journey Medical Publishes Full Phase 3 Trial Results for DFD-29
The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval.
Edgar Charles, MD, on Long-term Deucravacitinib Psoriasis Data
Quoin Reports Positive QRX003 “Whole Body” Pediatric Data for Netherton Syndrome
After just 2 weeks of twice-daily use, a pediatric patient saw visually improved skin with no adverse events.
LEO Pharma Reports Positive Results in Delgocitinib Trial for CHE
DELTA China follows the success of European and Canadian trials, reinforcing delgocitinib’s potential as a global treatment for CHE.
FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD
A PDUFA target action date has been set for October 13, 2025.
Current Clinical and Aesthetic Applications of Snail Mucin
Snail slime contains bioactive compounds that promote skin healing, hydration, and regeneration.
5-Year Study Backs Deucravacitinib’s Safety and Efficacy
The POETYK PSO LTE trial found deucravacitinib effective in sustaining PASI 75 and PASI 90 responses.
FDA Clears Zabalafin Hydrogel’s Investigational New Drug Application for AD
Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.
New Study Examines Connection Between Formulation and Benzene Levels in BPO Products
Barbieri et al evaluated product use, benzoyl peroxide concentration, days until expiration, and more.
Rezpegaldesleukin Receives Fast Track Designation for Moderate to Severe AD
Nektar Therapeutics’ investigational biologic targets the IL-2 receptor complex.
Delgocitinib Could Close Gap in Adolescent CHE Treatment
The drug, a JAK inhibitor, met all primary and secondary endpoints in a phase 3 trial for adolescent CHE.
Anaptys and Vanda Announce Global Licensing Agreement of Imsidolimab for GPP
The IL-36R antagonist has demonstrated its safety and efficacy for generalized pustular psoriasis in GEMINI-1 and GEMINI-2 studies.
Additional Evidence Supports Quoin’s QRX003 for Netherton Syndrome
QRX003 mimics the LEKTI protein to strengthen skin barriers and alleviate symptoms in patients with Netherton Syndrome.
Advances in Urticaria Care with Jason Hawkes, MD, MS
Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.
UCB Launches 320mg Single-Injection Bimekizumab
The new dosing option offers convenience for those managing plaque psoriasis, PsA, and hidradenitis suppurativa.
Clinicians to Watch for Recalled Supplement That May Cause Solar Purpura
Shanna Miranti, MPAS, PA-C, discusses the Umary hyaluronic acid tablets that were recalled in fall 2024.
Next-Gen Therapy: Advancing Topical Therapeutics
Mitragotri said new innovations like ionic liquid-based delivery systems can offer better treatment for immunodermatological conditions.
Ionic Liquids Boost Skin Drug Delivery
The innovative technology is unlocking new possibilities in dermatology by improving the solubility and permeability of drugs for topical use.
Looking Ahead to 2025 Dermatology Drug Approvals
Dermatology Times is reviewing some of the most anticipated PDUFA dates of the upcoming year.